An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay

BACKGROUND: Data from previous studies of the MVC-COV1901 vaccine, a subunit vaccine against SARS-CoV-2 based on the stable prefusion spike protein (S-2P) adjuvanted with CpG 1018 adjuvant and aluminum hydroxide, suggest that the vaccine is generally safe and elicits a good immune response in health...

Descripción completa

Detalles Bibliográficos
Autores principales: Torales, Julio, Cuenca-Torres, Osmar, Barrios, Laurentino, Armoa-Garcia, Luis, Estigarribia, Gladys, Sanabria, Gabriela, Lin, Meei-Yun, Antonio Estrada, Josue, Estephan, Lila, Cheng, Hao-Yuan, Chen, Charles, Janssen, Robert, Lien, Chia-En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671637/
https://www.ncbi.nlm.nih.gov/pubmed/36404171
http://dx.doi.org/10.1016/j.vaccine.2022.10.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671637/
https://www.ncbi.nlm.nih.gov/pubmed/36404171
http://dx.doi.org/10.1016/j.vaccine.2022.10.030

Ejemplares similares